Sage Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
A group of investment entities led by Madison Avenue Partners has filed an amended Schedule 13G, reporting zero beneficial ownership in Sage Therapeutics, Inc. common stock.
A group of investment entities led by Madison Avenue Partners LP has disclosed beneficial ownership of 9.7% of Sage Therapeutics, Inc.'s common stock.
The Vanguard Group has filed an amended Schedule 13G, reporting a 5.21% beneficial ownership stake in Sage Therapeutics Inc.
SCHEDULE 13G/A: BlackRock Discloses 7.2% Passive Stake in Sage Therapeutics
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 7.2% passive beneficial ownership stake in Sage Therapeutics Inc. as of March 31, 2025.
A group of investment entities associated with Madison Avenue, including Madison Avenue International LP and Eli Samaha, have disclosed a passive 8% beneficial ownership stake in Sage Therapeutics, Inc.
FMR LLC and Abigail P. Johnson have filed an Amendment No. 16 to their Schedule 13G, disclosing a beneficial ownership of 0.8% of Sage Therapeutics Inc.'s common stock as of February 28, 2025.
Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed an amended Schedule 13G indicating they are no longer beneficial owners of more than five percent of Sage Therapeutics, Inc.'s common stock.
RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a beneficial ownership of 4.9% of Sage Therapeutics, Inc.'s common stock as of December 31, 2024.
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 6.7% of Sage Therapeutics Inc.'s common stock as of December 31, 2024.
SCHEDULE 13G: Morgan Stanley Discloses Significant Stake in Sage Therapeutics, Holding 7.4% of Common Stock
Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed beneficial ownership of 7.4% of Sage Therapeutics, Inc.'s common stock as of December 31, 2024.
SCHEDULE 13G/A: Vanguard Group Discloses 7.9% Passive Stake in Sage Therapeutics
The Vanguard Group has filed an amended Schedule 13G, reporting a 7.9% passive ownership stake in Sage Therapeutics Inc. as of December 31, 2024.
BB Biotech AG and its subsidiary, Biotech Target N.V., have filed an updated Schedule 13G, disclosing a 1.9% passive ownership stake in Sage Therapeutics, Inc.